Search

A report from Johns Hopkins University discusses the development of post-transplant cyclophosphamide therapy for allogeneic blood or marrow transplantation (alloBMT). Traditionally, close HLA matching between donors and recipients has been considered crucial for successful transplantation, but this can be challenging for certain ethnic groups. Researchers at Johns Hopkins found that cyclophosphamide could effectively prevent graft-versus-host disease (GVHD) in animal models, leading to further investigation of its use in high doses for GVHD prophylaxis. Extensive studies have shown that high-dose post-transplantation cyclophosphamide (PTCy) can safely limit GVHD, making mismatched transplants a standard-of-care option. The beneficial effects of PTCy on GVHD appear to be independent of donor type, graft source, or conditioning regimen intensity. [Extracted from the article]

A recent study conducted by researchers at Kashan University of Medical Sciences in Iran explored the effects of L-carnitine on oocyte mitochondrial health and biomarkers in mice undergoing cyclophosphamide chemotherapy. The study found that L-carnitine, an antioxidant, can reduce the destructive effects of cyclophosphamide and enhance communication between oocytes and cumulus cells, potentially increasing fertility rates. The research involved analyzing gene expression levels and intracellular reactive oxygen species (ROS) in oocytes. These findings contribute to the understanding of improving oocyte competence during chemotherapy and its impact on fertility. [Extracted from the article]

A clinical trial, NCT06208280, is currently underway at RenJi Hospital in China to assess the safety and tolerability of F01 in treating autoimmune diseases. The trial is seeking around 20 participants with conditions such as systemic lupus erythematosus, antineutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathies, and diffuse cutaneous systemic sclerosis. The study consists of two stages: dose escalation and dose extension. The primary focus is on monitoring adverse events, serious adverse events, and abnormal laboratory test results. The trial is actively recruiting participants, and it is expected to be completed by December 2025. Contact information for the primary investigator is available for those interested in participating or obtaining more information. [Extracted from the article]

A recent study conducted at the University Hospital of Salamanca in Spain compared the effectiveness of different treatment regimens for relapsed/refractory multiple myeloma (RRMM). The study found that the combination of weekly carfilzomib, cyclophosphamide, and dexamethasone did not significantly improve outcomes compared to carfilzomib and dexamethasone alone. However, in a subgroup of patients who were refractory to lenalidomide, the addition of cyclophosphamide did show a significant benefit in terms of progression-free survival. Overall, the study concluded that the administration of weekly carfilzomib was safe and manageable in both treatment arms. [Extracted from the article]

A report from the Chinese Academy of Tropical Agricultural Sciences discusses research on the protective effects of Artocarpus heterophyllus Lam. (jackfruit) polysaccharides (JFP-Ps) on liver injury induced by cyclophosphamide (Cp) in mice. The study found that JFP-Ps exhibited antioxidant effects and immune regulatory roles, protecting against Cp-induced liver damage. Metabolomic analysis revealed that JFP-Ps were associated with various metabolic pathways related to liver protection. The research suggests that JFP-Ps have potential applications in alleviating liver injury. [Extracted from the article]

Researchers from Jilin Agricultural University in China have conducted a study on the optimization of the flavonoid extraction process from the stem and leaves of Epimedium Brevicornum (EBF) and its effects on cyclophosphamide-induced renal injury. Cyclophosphamide (CTX) is an alkylated antitumor drug used in cancer treatment, but it can cause renal toxicity. The researchers found that EBF, which contains the active substance icariin, may activate the Keap1-Nrf2 signaling pathway to reduce inflammation and oxidative stress in kidney tissue, potentially protecting against CTX-induced kidney damage. This research suggests that EBF could be a natural protective agent for CTX chemotherapy in the future. [Extracted from the article]

A recent report from Punjabi University in Punjab, India discusses the development of selective inhibitors for aldehyde dehydrogenase 1A1 (ALDH1A1) to overcome resistance to the anti-cancer drug cyclophosphamide (CP). The researchers used scaffold hopping analysis to identify a novel scaffold, benzimidazole, which showed significant inhibitory potential against ALDH1A1. Three compounds derived from this scaffold were found to reverse mafosfamide resistance in cell line assays. This research provides insights into potential strategies for overcoming resistance to cyclophosphamide therapy. [Extracted from the article]

The document provides information about a Phase 2 clinical trial, NCT06199427, which is being conducted to evaluate the effectiveness of a combined treatment approach for patients with inborn errors of immunity (IEI). The trial aims to assess various outcomes such as survival rates, incidence of graft versus host disease, engraftment, and organ toxicity. The study will use a specific regimen of drugs and is currently recruiting patients aged 0 months to 21 years. The trial is expected to be completed by December 31, 2027 and is being conducted by the Federal Research Institute of Pediatric Hematology, Oncology and Immunology in Russia. [Extracted from the article]

A recent study conducted at Tohoku University Hospital in Miyagi, Japan compared the outcomes of two different approaches to stem cell transplantation in adult patients with aplastic anemia. The study analyzed data from a nationwide registry and found that both approaches, post-transplantation cyclophosphamide (PTCy)-haploidentical transplantation and umbilical cord blood transplantation (UCBT), had similar overall survival rates at one year. However, PTCy-haploidentical transplantation had higher rates of neutrophil and platelet engraftment compared to UCBT. The study suggests that PTCy-haploidentical transplantation may be a promising alternative for adult patients with aplastic anemia. [Extracted from the article]

A recent toxicology research study conducted at Usak University in Turkey investigated the protective effects of resveratrol and Coenzyme Q10 against oxidative stress induced by cyclophosphamide, a drug used in the treatment of various diseases, including cancer. The study involved male rats divided into different groups, and the results showed that resveratrol and Coenzyme Q10, both separately and together, reversed the altered levels and enzyme activities caused by cyclophosphamide, as well as ameliorated DNA damage and histopathological changes. The findings suggest that resveratrol and Coenzyme Q10 may have potential protective effects against cyclophosphamide-induced toxicity. [Extracted from the article]

A recent study conducted by researchers at the American University Cairo provides insights into the metabolism and mechanism of action of the anticancer agent cyclophosphamide (CP). CP is commonly used in cancer chemotherapy and is activated by a liver enzyme to produce a cytotoxic metabolite. The study used computational analysis to investigate the different metabolic phases and the mechanism by which CP exerts its cytotoxic effects. The findings of this study may contribute to the development of new and improved anticancer drugs in the future. [Extracted from the article]

A recent study conducted by researchers at the University of Baghdad in Iraq explored the potential hepatoprotective effect of quercetin, a natural compound, in male rats exposed to cyclophosphamide, a chemotherapy drug. The study involved four groups of rats, including a control group, a group treated with cyclophosphamide, a group treated with quercetin, and a group treated with both quercetin and cyclophosphamide. The researchers analyzed various biochemical markers and found that the group treated with both quercetin and cyclophosphamide showed a significant reduction in liver damage markers compared to the group treated with cyclophosphamide alone. The study suggests that quercetin has the potential to protect liver tissues from the toxic effects of cyclophosphamide. [Extracted from the article]

A recent study conducted by researchers at Jazan University in Saudi Arabia explored the potential therapeutic effects of sesamin, an antioxidant derived from plants, on cyclophosphamide-induced hepatotoxicity. Cyclophosphamide is a commonly used chemotherapy drug that can cause significant liver damage. The study found that sesamin treatment reduced liver markers, cytokines, and caspase-3, while improving antioxidants and antioxidant enzymes. These findings suggest that sesamin may have a role as an adjunct therapy to reduce hepatotoxicity in chemotherapy. [Extracted from the article]

A study conducted at Prince Sattam bin Abdulaziz University in Saudi Arabia explored the potential benefits of a flavonoid called amentoflavone (AMV) in mitigating the pulmonary toxicities caused by cyclophosphamide (CPA), an alkylating agent used in cancer treatment. The study found that AMV dose-dependently improved the pulmonary toxicities induced by CPA by modulating various biological pathways, including antioxidant, anti-inflammatory, and apoptosis-modulating effects. The research suggests that AMV may have potential in reducing the harmful effects of CPA on the lungs. The study was supported by The Deputyship For Research & Innovation, Ministry of Education in Saudi Arabia. [Extracted from the article]

Researchers at Changchun University of Chinese Medicine have published new data on cyclophosphamide therapy. The study focuses on the immunological activity of a purified acidic polysaccharide fraction called AMPA, derived from Armillaria mellea crude polysaccharide. In vitro experiments showed that AMPA treatment increased levels of immune factors and activated the TLR4/MyD88/NF-kB signaling pathway. Metabolomic analysis revealed that AMPA modulated six endogenous metabolites in mice, suggesting its potential as a therapeutic biomarker for immunodeficiency. The results highlight the potential of AMPA as a health food or drug that enhances immunity. [Extracted from the article]

A recent study conducted by researchers at Mashhad University of Medical Sciences in Iran examined the therapeutic effects of Medicago sativa (M. sativa) against cyclophosphamide-induced toxicity in rats. The study found that M. sativa extract, particularly at a dosage of 400 mg/kg, showed significant improvements in platelet count and oxidative stress markers, comparable to the effects of dexamethasone. These findings suggest that M. sativa may have potential therapeutic benefits in mitigating the toxic effects of cyclophosphamide. Further research is needed to explore the full extent of these effects. [Extracted from the article]

A patent has been issued for a bispecific antibody that targets CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma (DLBCL). The patent describes a method for treating DLBCL by administering the bispecific antibody along with the standard R-CHOP regimen. The patent provides specific dosing regimens and administration schedules for the bispecific antibody in combination with other drugs. The assignee for the patent is Genmab A/S. This method is intended for the treatment of DLBCL in human subjects and may be used in combination with other therapies. [Extracted from the article]

A study conducted by researchers at Osun State University explores the potential therapeutic effects of sodium acetate on cardiac toxicities caused by cyclophosphamide in Wistar rats. The study found that acetate co-administration significantly attenuated cyclophosphamide-induced cardiotoxicity by inhibiting NF-kB signaling and suppressing caspase-3-dependent apoptosis. These findings suggest that acetate may have cardio-protective effects against cyclophosphamide-induced cardiotoxicity. [Extracted from the article]

A report from Xinxiang Medical University in China discusses the potential benefits of Danggui Buxue Decoction (DBD) in alleviating myelosuppression after chemotherapy. The researchers conducted experiments on rats and in vitro to study the effects of DBD on beta-hydroxybutyric acid (beta-OHB) metabolism and oxidative stress. The results showed that DBD could regulate beta-OHB metabolism and suppress oxidative stress, leading to improved blood cell counts and reduced HDAC1 activity and oxidative stress indices. The study suggests that DBD, a traditional Chinese medicine, may have potential therapeutic effects in alleviating myelosuppression caused by chemotherapy. [Extracted from the article]

A recent study conducted in Tianjin, China explored the use of low-dose cyclophosphamide (PDCy) as a prophylactic treatment for severe acute graft-versus-host disease (aGVHD) in patients who had relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study found that the PDCy regimen effectively reduced the incidence of severe aGVHD without compromising therapeutic response rates. However, the researchers noted that further verification through longer follow-up and larger prospective randomized studies is needed. This research provides valuable insights into potential treatment options for aGVHD after allo-HSCT. [Extracted from the article]

A recent study conducted at Seoul National University Hospital in South Korea provides new data on the clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic leukemia (T-LGLL). The study included 67 patients, with a median age of 60 years, and found that 55% of patients were symptomatic and 37% had splenomegaly. The most frequently used treatments were cyclophosphamide, methotrexate, and cyclosporin A, with similar overall response rates. Splenomegaly was associated with an increased response rate to first-line therapy, while thrombocytopenia was associated with decreased response rates. The study provides valuable information for clinical decision-making regarding T-LGLL treatment. [Extracted from the article]

A rare case report from the University of Baghdad discusses the emergence of acute promyelocytic leukemia (APL) in a patient with granulomatosis with polyangiitis (GPA) during treatment with cyclophosphamide. GPA is an autoimmune disease that affects multiple organs and causes inflammation in small blood vessels. The case highlights the unique occurrence of APL in a GPA patient undergoing cyclophosphamide therapy. Previous research has reported a similar case with a different medication. Treatment for GPA involves achieving and maintaining remission, but cyclophosphamide-based regimens have been associated with an increased risk of hematological malignancies. The patient in this case was treated with all-trans retinoic acid, arsenic trioxide, and steroids. [Extracted from the article]

A study conducted at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, investigated the effectiveness and safety of different infusion durations of cyclophosphamide (CTX) plus granulocyte colony-stimulating factor (G-CSF) for peripheral blood stem cell mobilization in patients with newly diagnosed multiple myeloma (NDMM). The study found that a 24-hour continuous infusion of CTX plus G-CSF resulted in improved mobilization efficiency and equivalent toxicity compared to a shorter infusion time. The research suggests that this regimen could be beneficial for NDMM patients undergoing stem cell mobilization. [Extracted from the article]

A case study from Nagaoka Red Cross Hospital in Niigata, Japan, reports on the successful treatment of subarachnoid hemorrhage (SAH) associated with eosinophilic granulomatosis with polyangiitis (EGPA) using glucocorticoid therapy, cyclophosphamide, and mepolizumab. SAH is a rare but serious complication of EGPA, and the exact cause is not fully understood. Prompt intensive immunosuppressive therapy, along with mepolizumab, an anti-interleukin-5 monoclonal antibody, was found to induce remission of SAH. This research suggests that mepolizumab should be considered as a treatment option for SAH associated with EGPA. [Extracted from the article]

A recent study conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts explored the use of metronomic chemotherapy in combination with the antiangiogenic agent bevacizumab for the treatment of metastatic breast cancer. The study found that the combination therapy improved progression-free survival (PFS) compared to metronomic chemotherapy alone, although there was no significant difference in overall survival (OS). The researchers concluded that oral metronomic chemotherapy alone has limited activity in advanced breast cancer. This study provides valuable insights into potential treatment options for patients with metastatic breast cancer. [Extracted from the article]

A recent study conducted by researchers at the University of Tokyo explores the role of cellular senescence in cyclophosphamide-induced primary ovarian insufficiency (POI). The study found that young female cancer patients undergoing chemotherapy with cyclophosphamide are at risk of developing POI. The researchers investigated whether cellular senescence is involved in this process and whether treatment with senolytics, such as dasatinib and quercetin, can rescue ovarian damage. The study concluded that targeting senescent cells with senolytics may be a promising strategy to protect against cyclophosphamide-induced ovarian damage and improve fertility outcomes. [Extracted from the article]

A recent study conducted by researchers at Louisiana State University Health Sciences Center-Shreveport analyzed the real-world data on chemotherapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The researchers obtained data from the FDA Adverse Events Report System (FAERS) and found that cyclophosphamide was the most common drug associated with MDS/AML, followed by lenalidomide and etoposide. The study also revealed that MDS/AML was more common with etoposide compared to cyclophosphamide or lenalidomide. The researchers emphasized the importance of discussing the risks and benefits of these drugs with patients before treatment planning. [Extracted from the article]

A recent study conducted by researchers at Rush University in Chicago, Illinois, has found that post-transplant cyclophosphamide (PTCy) may be associated with an increased risk of bacterial infections in patients undergoing hematopoietic cell transplantation (HCT). The study included patients receiving haploidentical or matched sibling donor HCT for acute leukemias or myelodysplastic syndrome. The findings showed that patients receiving PTCy had a higher incidence of bacterial infections compared to those receiving other forms of graft-versus-host disease prophylaxis. The researchers recommend careful monitoring for bacterial infections in patients receiving PTCy. [Extracted from the article]

A recent study conducted at the Sidney Kimmel Comprehensive Cancer Center has explored the outcomes of multiple myeloma (MM) patients who underwent allogeneic stem cell transplant (allo-SCT) with post-transplant cyclophosphamide. The study analyzed data from 57 MM patients who received allo-SCT at Thomas Jefferson University Hospital from 1996 to 2023. The results showed that allo-SCT can be curative for approximately one-third of MM patients with high-risk features or relapsed/refractory disease. The use of post-transplant cyclophosphamide, in combination with contemporary MM treatments, significantly increased the survival of allo-SCT MM patients in the modern era. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital in Hangzhou, China, explored the use of haploidentical stem cell transplantation (haplo-HSCT) as an alternative treatment for aplastic anemia (AA) patients who do not have a matched sibling donor. The study used a modified post-transplantation cyclophosphamide (PTCY) strategy, which included the administration of anti-thymoglobulin/antilymphocyte globulin, fludarabine, thiotepa, busulfan, and modified low and high-dose cyclophosphamide. The results showed successful engraftment in all 15 patients, with a median follow-up time of 267 days. The study demonstrated promising outcomes with prolonged survival and reduced complications for AA patients. [Extracted from the article]

A recent study conducted at Jiangxi Province People's Hospital in China explored the impact of adipose-derived mesenchymal stem cell (AdMSC)-exosomes on cyclophosphamide-induced cardiotoxicity in rats. The researchers successfully isolated AdMSCs and AdMSCs-Exos, which were found to target rat hearts. The study concluded that AdMSCs-Exos alleviated cardiotoxicity by reducing oxidative stress, apoptosis, and autophagy in rats. This research provides new insights into potential treatments for cyclophosphamide-induced cardiotoxicity. [Extracted from the article]

A recent report from the Northside Hospital Cancer Institute in Atlanta, Georgia discusses the use of cyclophosphamide therapy in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who undergo non-myeloablative peripheral blood stem cell transplant. The study found that post-transplant maintenance with cyclophosphamide did not have a significant impact on overall survival, progression-free survival, relapse, non-relapse mortality, or acute graft-versus-host disease. The researchers suggest that further investigation is needed to determine the efficacy of post-transplant maintenance in this setting and to explore the potential combination of hypomethylating agents with other drugs to reduce relapse. [Extracted from the article]

A recent study conducted at Toranomon Hospital in Tokyo, Japan compared two different myeloablative conditioning (MAC) regimens for allogeneic stem cell transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The standard regimen, cyclophosphamide combined with total-body irradiation (Cy/TBI), was compared to a regimen of fludarabine, melphalan, and total-body irradiation (Flu/Mel/TBI). The study found that the Flu/Mel/TBI regimen had a significantly lower 5-year cumulative relapse rate compared to the Cy/TBI regimen, with no significant difference in non-relapse mortality. These findings suggest that Flu/Mel/TBI may be a reasonable alternative to Cy/TBI and may be a superior MAC regimen. [Extracted from the article]

A researcher from Hospital Nove de Julho in Sao Paulo, Brazil has conducted a retrospective study comparing the use of post-transplant cyclophosphamide (PTCy) with other graft-versus-host disease (GVHD) prophylaxis strategies in patients undergoing allogeneic peripheral blood stem cell transplantation (PBSCT). The study found that PTCy demonstrated similar clinical outcomes to other GVHD prophylaxis strategies, without an increased risk of infections or mortality. This suggests that PTCy can be considered a viable, safe, and cost-effective option for GVHD prophylaxis in HLA-matched and HLA-mismatched transplants. [Extracted from the article]

A study conducted at Hospital del Salvador in Santiago, Chile, examined the outcomes of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide (Haplo-PTCy) in adult patients. The study found that Haplo-PTCy is a feasible treatment option in low-and-middle-income countries, with encouraging survival rates and acceptable rates of acute graft-versus-host disease and relapse. The research provides valuable data on the use of Haplo-PTCy in the Chilean National Health System and contributes to the understanding of cell transplantation in neoplastic diseases. [Extracted from the article]

A study conducted by Dokkyo Medical University investigated the risk factors and clinical manifestations of late cytomegalovirus (CMV) disease after hematopoietic cell transplantation (HCT). The study found that pre-emptive therapy and letermovir prophylaxis were effective in preventing CMV disease within the first 100 days after HCT. However, late-onset CMV disease was still observed, with gastrointestinal disease and pneumonia being the most common manifestations. The study identified high-dose steroid treatment, post-transplant cyclophosphamide, and CMV reactivation before day 100 as risk factors for late CMV disease. The researchers concluded that improved strategies are needed to prevent late CMV disease in high-risk patients. [Extracted from the article]

A recent report from TangDu Hospital in Xi'an, China discusses the potential chemoprotective effect of baicalin against ovarian toxicity induced by cyclophosphamide (CP) in mice. The study found that baicalin increased apoptosis and caused cell cycle arrest in ovarian cancer cells. It also reduced the level of TGF-b, increased body weight, reduced tumor volume, and increased the levels of estrogen and progesterone in mice. Baicalin also decreased oxidative stress and inflammation markers. The researchers concluded that baicalin has the potential to protect against ovarian toxicity by altering TGF-b and inflammatory pathways. [Extracted from the article]

A recent study conducted in China compared the effectiveness and safety of two different treatment regimens for acquired hemophilia A (AHA), a serious bleeding disorder. The study found that a single-dose rituximab plus glucocorticoid regimen was non-inferior to the standard cyclophosphamide plus glucocorticoid regimen in terms of achieving complete remission and partial remission. The single-dose rituximab regimen showed similar efficacy and safety without the reported risks of secondary malignancies or reproductive toxicity associated with cyclophosphamide. This treatment option may be recommended as a first-line therapy for AHA, particularly in China where there is a trend of younger AHA patients. [Extracted from the article]

A recent study conducted by Case Western Reserve University evaluated the effectiveness of different therapeutic options for treating acquired hemophilia A (AHA), a rare disorder characterized by the emergence of neutralizing antibodies to factor VIII. The main treatment strategy for AHA involves controlling bleeding with factor VIII bypassing agents and eradicating the autoantibodies using immunosuppressive therapy (IST). The study compared the effectiveness of cyclophosphamide and rituximab as first-line therapies for rapid antibody elimination and relapse prevention. The results showed that rituximab was more effective than cyclophosphamide in achieving rapid remission and reducing the incidence of relapse. The study also found that the initial inhibitor titer may serve as a useful predictor of disease course, potentially guiding therapeutic decision-making. Further research is needed to confirm these findings and investigate other factors influencing therapeutic outcomes in patients with AHA. [Extracted from the article]

A recent study conducted in Alberta, Canada, examined the quality of care and guideline adherence for acquired hemophilia A (AHA), a life-threatening bleeding disorder. The study found gaps in care, including overuse of cyclophosphamide in patients with low-titre inhibitors, prolonged duration of cyclophosphamide, and inappropriate use of intravenous immunoglobulin (IVIG) and plasma. The researchers emphasized the need for centralized care in specialized centers and education initiatives to improve patient outcomes. The study highlights the risks associated with aggressive cytotoxic therapy and the importance of following international consensus guidelines. [Extracted from the article]

A recent report from Augusta University discusses the use of prephase cyclophosphamide (pCy) as a treatment option for patients with aggressive lymphomas who are not eligible for intensive chemotherapy. The study found that pCy allowed 78% of patients to receive definitive therapy for their lymphoma. The treatment was well-tolerated and had a limited side effect profile. The researchers suggest that pCy should be considered in clinical trials to better represent real-world patients. [Extracted from the article]

A recent report from Harvard Medical School presents new data on stem cell transplants. The study compared two different treatments for graft-versus-host disease (GVHD) prophylaxis after hematopoietic cell transplant (HCT). The researchers found that post-transplant cyclophosphamide (PT-Cy) significantly improved GVHD-free Relapse-Free Survival compared to the other treatment, but overall survival was not significantly different. The study also revealed that PT-Cy led to a less diverse T cell repertoire, which has implications for both the efficacy and toxicity of the treatment. The findings suggest a novel mechanism for controlling GVHD with PT-Cy but also increase the risk of infections. [Extracted from the article]

A recent study conducted by researchers at Sun Yat-sen University in China focused on the use of cyclophosphamide therapy for the treatment of Granulomatous polyangiitis (GPA), a rare autoimmune disease. The study explored the combination treatment of telitacicept, cyclophosphamide, and glucocorticoids in a 64-year-old male patient with severe GPA. The patient showed significant improvement in renal function, hearing, and lung lesions after receiving this treatment. The researchers concluded that this combination therapy may be a safe and feasible option for induction therapy in GPA patients with organ-threatening disease, but further clinical trials are needed to validate its efficacy and safety. [Extracted from the article]

A recent study conducted by researchers at the Clinical and Translational Science Institute in Los Angeles has found that a combination of post-transplant cyclophosphamide (PTCy) and abatacept (CTLA4Ig) can be effective in preventing chronic graft-versus-host disease (GVHD) after an allogeneic stem cell transplantation. The study involved 40 patients with hematologic malignancies who received either the PTCy and abatacept regimen or the standard of care (SOC) treatment with tacrolimus and methotrexate. The results showed that the PTCy and abatacept regimen had a significantly lower rate of chronic GVHD compared to the SOC treatment. The researchers concluded that the PTCy and abatacept regimen is feasible, well-tolerated, and associated with a favorable outcome in terms of chronic GVHD prevention. [Extracted from the article]

A recent report discusses research findings on lymphoma, specifically comparing the use of bendamustine versus fludarabine/cyclophosphamide (flu/cy) lymphodepletion chemotherapy in adult patients receiving CD19 CAR-T cell therapy. The study aimed to investigate the outcomes and toxicity profile associated with the use of bendamustine compared to flu/cy in patients with B-cell non-Hodgkin lymphoma (B-NHL). The results showed that bendamustine had a more favorable toxicity profile compared to flu/cy, with lower rates of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and neutropenia. However, longer follow-up is needed to assess potential differences in survival between the two groups. [Extracted from the article]

A recent study conducted at Hackensack University Medical Center compared the use of two different lymphodepleting regimens, fludarabine/cyclophosphamide (Flu/Cy) and bendamustine (B), in patients with relapsed multiple myeloma who received anti-BCMA chimeric antigen receptor T-cell therapy (CAR-T). The study found that the use of bendamustine as a lymphodepleting regimen may have a negative impact on the outcomes of patients receiving CAR-T therapy for relapsed multiple myeloma. Although the follow-up period was short, the study suggests that fludarabine/cyclophosphamide may be a more effective regimen. However, further research is needed to confirm these findings. [Extracted from the article]

A recent report from Peking University Third Hospital in Beijing, China, discusses a rare case of IgG4-related skin disease (IgG4-RSD) in a middle-aged male patient. The patient presented with generalized angiolymphoid hyperplasia with eosinophilia (ALHE)-like lesions, but no other organ involvement. The patient was successfully treated with oral glucocorticoid and cyclophosphamide, resulting in complete remission. The patient remained in remission with no relapse or disease progression during an 8-year follow-up period. This research highlights the importance of recognizing and treating IgG4-RSD to prevent delayed identification and treatment. [Extracted from the article]

A study conducted at Clinica Ruiz in Puebla, Mexico, explored the possibility of reducing the doses of post-transplantation cyclophosphamide (PTCy) in haploidentical stem cell allografts. The researchers found that reducing the dose of PTCy did not significantly affect age, sex, hematological recovery, or the type of conditioning regimen. The median overall survival for the group receiving the conventional dose of PTCy was 5.7 months, while the group receiving the reduced dose had a median overall survival of 6.4 months. These preliminary findings suggest that reducing the dose of PTCy may be a viable option for haploidentical stem cell transplantation, and further randomized studies are warranted. [Extracted from the article]

A new study conducted at the Affiliated People's Hospital of Ningbo University in China explores the use of post-transplantation cyclophosphamide (PTCy) in children with acute leukemia. PTCy is known to reduce the incidence of graft versus host disease (GVHD) in adults with hematologic malignancies, but its effectiveness in children is limited. To address this, the researchers combined PTCy with an intensified conditioning regimen involving fludarabine, cytarabine, busulfan, and anti-thymocyte globulin. The study found that this combination significantly reduced the incidence of acute GVHD and showed potential for improving GVHD-free relapse-free survival. The findings suggest that this intensified conditioning regimen could be effective for treating acute leukemia in children. [Extracted from the article]

A recent study conducted by Maastricht University Medical Center has found that certain immunomodulating chemotherapeutic drugs, including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, can pass through the placenta during pregnancy and potentially impact the development of the immune system in exposed infants. The study examined three infants exposed to these drugs during pregnancy and found that they experienced various immune system effects, such as B-cell lymphopenia, hypogammaglobinemia, neutropenia, and decreased response to immunization. The researchers recommend immune monitoring of exposed infants. Further information on this research can be found in the journal article published by Clinical Immunology Communications. [Extracted from the article]